Maxim Group Increases BeiGene (BGNE) Price Target to $225.00

BeiGene (NASDAQ:BGNE) had its target price upped by stock analysts at Maxim Group from $200.00 to $225.00 in a report issued on Friday. The firm currently has a “buy” rating on the stock. Maxim Group’s target price would suggest a potential upside of 18.98% from the stock’s current price.

Other analysts have also recently issued research reports about the company. Zacks Investment Research raised BeiGene from a “hold” rating to a “buy” rating and set a $190.00 target price for the company in a research report on Tuesday, May 1st. BidaskClub raised BeiGene from a “hold” rating to a “buy” rating in a research report on Wednesday, January 31st. Ladenburg Thalmann reaffirmed a “buy” rating and issued a $172.00 target price on shares of BeiGene in a research report on Thursday, March 1st. They noted that the move was a valuation call. ValuEngine raised BeiGene from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Robert W. Baird reaffirmed a “hold” rating and issued a $138.00 target price on shares of BeiGene in a research report on Thursday, March 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $173.00.

Shares of NASDAQ BGNE opened at $189.11 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.12 and a current ratio of 11.18. The firm has a market capitalization of $9.81 billion, a P/E ratio of -84.80 and a beta of 0.29. BeiGene has a 52-week low of $184.00 and a 52-week high of $187.13.

BeiGene (NASDAQ:BGNE) last issued its earnings results on Wednesday, May 9th. The company reported ($2.03) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.62) by ($0.41). The company had revenue of $32.54 million during the quarter, compared to analyst estimates of $16.88 million. During the same quarter last year, the firm earned ($1.27) EPS. research analysts expect that BeiGene will post -8.23 EPS for the current fiscal year.

In other BeiGene news, CEO John Oyler sold 99,000 shares of the business’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $145.63, for a total value of $14,417,370.00. Following the completion of the sale, the chief executive officer now owns 93,883 shares of the company’s stock, valued at $13,672,181.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Ji Li sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $146.88, for a total value of $1,468,800.00. Following the completion of the sale, the executive vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $1,468,800. The disclosure for this sale can be found here. In the last ninety days, insiders sold 194,210 shares of company stock valued at $29,041,676. 19.90% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC acquired a new stake in shares of BeiGene in the fourth quarter worth about $182,000. Comerica Bank acquired a new stake in shares of BeiGene in the fourth quarter worth about $246,000. Mackenzie Financial Corp acquired a new stake in shares of BeiGene in the fourth quarter worth about $250,000. Jefferies Group LLC acquired a new stake in shares of BeiGene in the fourth quarter worth about $283,000. Finally, Quantbot Technologies LP acquired a new stake in shares of BeiGene in the first quarter worth about $290,000. 51.88% of the stock is owned by institutional investors.

About BeiGene

BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Biopharmx Corp  Short Interest Down 0.9% in May
Biopharmx Corp Short Interest Down 0.9% in May
Cormedix  Sees Significant Decrease in Short Interest
Cormedix Sees Significant Decrease in Short Interest
Short Interest in Northern Dynasty Minerals, Ltd.  Drops By 4.9%
Short Interest in Northern Dynasty Minerals, Ltd. Drops By 4.9%
JPMorgan Chase & Co. Analysts Give Covestro  a €105.00 Price Target
JPMorgan Chase & Co. Analysts Give Covestro a €105.00 Price Target
Encavis  Given a €7.80 Price Target by Baader Bank Analysts
Encavis Given a €7.80 Price Target by Baader Bank Analysts
Warburg Research Analysts Give Dürr  a €100.00 Price Target
Warburg Research Analysts Give Dürr a €100.00 Price Target


Leave a Reply

© 2006-2018 Ticker Report. Google+.